Axon demyelination contributes to the loss of sensory and motor function following injury or disease in the central nervous system. Numerous reports have demonstrated that myelination can be achieved in neuron/oligodendrocyte co-cultures. However, the ability to selectively treat neuron or oligodendrocyte (OL) cell bodies in co-cultures improves the value of these systems when designing mechanism-based therapeutics. We have developed a microfluidic-based compartmentalized culture system to achieve segregation of neuron and OL cell bodies while simultaneously allowing the formation of myelin sheaths. Our microfluidic platform allows for a high replicate number, minimal leakage, and high flexibility. Using a custom built lid, fit with platinum electrodes for electrical stimulation (10-Hz pulses at a constant 3 V with ~190 kΩ impedance), we employed the microfluidic platform to achieve activity-dependent myelin segment formation. Electrical stimulation of dorsal root ganglia resulted in a fivefold increase in the number of myelinated segments/mm² when compared to unstimulated controls (19.6 ± 3.0 vs. 3.6 ± 2.3 MBP+ segments/mm²). This work describes the modification of a microfluidic, multi-chamber system so that electrical stimulation can be used to achieve increased levels of myelination while maintaining control of the cell culture microenvironment.
Purpose To evaluate the immediate and long-term safety as well as thrombus-capturing efficacy for 5 weeks after implantation of an absorbable inferior vena cava (IVC) filter in a swine model. Materials and Methods This study was approved by the institutional animal care and use committee. Eleven absorbable IVC filters made from polydioxanone suture were deployed via a catheter in the IVC of 11 swine. Filters remained in situ for 2 weeks (n = 2), 5 weeks (n = 2), 12 weeks (n = 2), 24 weeks (n = 2), and 32 weeks (n = 3). Autologous thrombus was administered from below the filter in seven swine from 0 to 35 days after filter placement. Fluoroscopy and computed tomography follow-up was performed after filter deployment from weeks 1-6 (weekly), weeks 7-20 (biweekly), and weeks 21-32 (monthly). The infrarenal IVC, lungs, heart, liver, kidneys, and spleen were harvested at necropsy. Continuous variables were evaluated with a Student t test. Results There was no evidence of IVC thrombosis, device migration, caval penetration, or pulmonary embolism. Gross pathologic analysis showed gradual device resorption until 32 weeks after deployment. Histologic assessment demonstrated neointimal hyperplasia around the IVC filter within 2 weeks after IVC filter deployment with residual microscopic fragments of polydioxanone suture within the caval wall at 32 weeks. Each iatrogenic-administered thrombus was successfully captured by the filter until resorbed (range, 1-4 weeks). Conclusion An absorbable IVC filter can be safely deployed in swine and resorbs gradually over the 32-week testing period. The device is effective for the prevention of pulmonary embolism for at least 5 weeks after placement in swine. RSNA, 2017.
Purpose
Determine the in-vitro clot capture efficiency (CCE) of an investigational absorbable inferior vena cava filter (IVCF) versus the Greenfield IVCF.
Materials and Methods
Investigational absorbable and Greenfield filters were challenged with polyacrylamide (PAM) clot surrogates ranging from 3×5 to 10×24 mm (dia. × length) in a flow loop simulating the venous system. Filters were challenged with clots until CCE standard error of 5% or less was achieved under binomial statistics. Pressure gradients across the filters were measured for the largest size clot, enabling calculation of forces on the filter.
Results
The absorbable IVCF in-vitro CCE was statistically similar to the Greenfield filter for all clot sizes apart from the 3×10 mm clot, where there was statistically significant difference between filter CCE’s (absorbable filter: 59%, Greenfield: 31%, p=0.0001). CCE ranged from an average 32% for the 3×5 clot to 100% for 7×10 mm and larger clots for the absorbable IVCF. Pressure gradient across the absorbable filter with 10×24 mm clot averaged 0.14 mmHg, corresponding to a net force on the filter of 2.1×10−3 N, compared to 0.39 mmHg or 5.8×10−3 N (p<0.001) for the Greenfield filter.
Conclusions
CCE of the absorbable filter was statistically similar to, or an improvement upon, the Greenfield stainless steel filter for all clot sizes tested. CCE of the Greenfield filter in this study aligned with data from previous studies. Given the efficacy of the Greenfield filter in attenuating the risk of pulmonary embolism, the current study suggests the absorbable filter may be a viable candidate for subsequent human testing.
The unlimited growth that occurs in tumors requires telomere maintenance. Yet, a portion of human tumors lack telomerase, and maintain telomeres using recombination-based mechanisms. Studies in other model organisms indicate that two different pathways of recombination-based mechanisms impact telomere maintenance and rely on the DNA repair proteins Rad50 and Rad51. In the Rad50-dependent pathway telomere recombination occurs within the telomere repeats. In contrast, recombination using the Rad51-dependent pathway occurs within repetitive sequences in the subtelomeres. Using a mouse B-cell lymphoma model lacking telomerase, Eμmyc+mTR-/-, and immortalized fibroblast cells lacking the RNA component of telomerase (mTR-/-) we have examined the impact of inhibiting Rad50 and Rad51a on telomere recombination. We find inhibiting Rad50 or Rad51a in Eμmyc+mTR-/- B-cell lymphomas, and in mTR-/- immortalized fibroblasts, has a synergistic effect on DNA damage sensitivity to mitomycin but not camptothecin. Inhibiting Rad50 in telomerase deficient cells also results in telomere shortening and in some tumors, reduced growth. In contrast, when Rad50 or Rad51a is inhibited in cells with telomerase, DNA damage sensitivity from mitomycin is not observed when compared to cells expressing a control shRNA. In addition inhibiting Rad50 in cells with telomerase does not significantly impact telomere length or recombination. Next we developed a comparative genomic hybridization (aCGH) approach that detects recombination events in the subtelomeres. Using these subtelomere arrays we find B-cell lymphomas lacking telomerase exhibit a significant increase in subtelomere recombination compared to primary cells. We also examined the impact of inhibiting Rad50 on subtelomere recombination events. Our findings using aCGH suggest that inhibiting Rad50 does not impact subtelomere recombination in Eμmyc+mTR-/- B-cell lymphomas. Overall, our findings suggest that inhibiting either Rad50 or Rad51a in mTR-/- cells has a synergistic impact on the sensitivity to DNA damaging agents in contrast to cells with mTR+/+. Currently we are testing the impact of inhibiting Rad51a on subtelomere recombination. In addition these results further support that Rad50 contributes to telomere recombination mechanisms in tumors lacking telomerase and will provide insight into the mechanism of subtelomere recombination in mammalian cells.
Disclosures:
No relevant conflicts of interest to declare.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.